Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evanthia Galanis

Showing results (21-30 of 196) with videos related to

Pageof 20
Sort By:
Handbook of Clinical Neurology|March 8, 2016
GlioblastomaHans-Georg Wirsching, Evanthia Galanis, Michael Weller
Nature Clinical Practice. Oncology|January 30, 2007
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progressTa-Chiang Liu, Evanthia Galanis, David Kirn
Cancers|February 25, 2022
PARP Inhibitors in Glioma: A Review of Therapeutic OpportunitiesHao-Wen Sim, Evanthia Galanis, Mustafa Khasraw
Molecular Diagnosis & Therapy|December 27, 2023
Personalizing Oncolytic Immunovirotherapy ApproachesGeorgios M Stergiopoulos, Ianko Iankov, Evanthia Galanis
Frontiers in Oncology|January 19, 2016
Aurora-A Kinase as a Promising Therapeutic Target in CancerAntonino B D'Assoro, Tufia Haddad, Evanthia Galanis
Virus Research|January 27, 2019
A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cellsCheyne Kurokawa, Ianko D Iankov, Evanthia Galanis
Vaccine|December 25, 2010
Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating proteinIanko D Iankov, Iana H Haralambieva, Evanthia Galanis
Vaccine|August 17, 2013
Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogensIanko D Iankov, Mark J Federspiel, Evanthia Galanis
Human Vaccines & Immunotherapeutics|December 4, 2015
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccinationAline Baldo, Evanthia Galanis, Frédéric Tangy, et al.
Current Treatment Options in Oncology|June 19, 2024
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant GliomasGeorgios M Stergiopoulos, Susanna C Concilio, Evanthia Galanis
Pageof 20

Showing results (21-30 of 196) with videos related to

Sort By:
Pageof 20
Handbook of Clinical Neurology|March 8, 2016
GlioblastomaHans-Georg Wirsching, Evanthia Galanis, Michael Weller
Nature Clinical Practice. Oncology|January 30, 2007
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progressTa-Chiang Liu, Evanthia Galanis, David Kirn
Cancers|February 25, 2022
PARP Inhibitors in Glioma: A Review of Therapeutic OpportunitiesHao-Wen Sim, Evanthia Galanis, Mustafa Khasraw
Molecular Diagnosis & Therapy|December 27, 2023
Personalizing Oncolytic Immunovirotherapy ApproachesGeorgios M Stergiopoulos, Ianko Iankov, Evanthia Galanis
Frontiers in Oncology|January 19, 2016
Aurora-A Kinase as a Promising Therapeutic Target in CancerAntonino B D'Assoro, Tufia Haddad, Evanthia Galanis
Virus Research|January 27, 2019
A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cellsCheyne Kurokawa, Ianko D Iankov, Evanthia Galanis
Vaccine|December 25, 2010
Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating proteinIanko D Iankov, Iana H Haralambieva, Evanthia Galanis
Vaccine|August 17, 2013
Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogensIanko D Iankov, Mark J Federspiel, Evanthia Galanis
Human Vaccines & Immunotherapeutics|December 4, 2015
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccinationAline Baldo, Evanthia Galanis, Frédéric Tangy, et al.
Current Treatment Options in Oncology|June 19, 2024
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant GliomasGeorgios M Stergiopoulos, Susanna C Concilio, Evanthia Galanis
Pageof 20